Compare Funko Inc (FNKO) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Funko Inc vs TG Therapeutics Inc — how do they compare? Funko Inc trades at $6.44 (market cap $363.97M), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 22.4× Funko Inc's market cap, and TG Therapeutics Inc is more actively traded (1,735,121 versus 1,422,651). Which is the better fit depends on your goals — on Pluang, investors hold Funko Inc for 33 Days and TG Therapeutics Inc for 16 Days on average.
| FNKO | TGTX | |
|---|---|---|
Market Cap | $363.97M | $8.16B |
Volume | 1,422,651 | 1,735,121 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.10 | $59.06 |
52-Week Low | $2.81 | $26.94 |
Typical Hold Time | 33 Days | 16 Days |
Enterprise Value | $584.62M | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Funko (FNKO) trades at $6.50, up 3.01% today, with strong technical momentum showing bullish moving average signals. The company reported mixed Q2 2026 results with revenue growth of 7% to $207.7 million and significant EBITDA improvement, though net income remains negative. Analyst consensus is mixed with 42.9% buy ratings and a $7.58 price target, representing 16.6% upside potential from current levels.
Investment outlook balances improving operational metrics against persistent profitability challenges. The stock offers potential upside based on analyst targets and recent earnings beats, but risks include negative net margins, volatile cash flows, and high debt levels that could pressure shareholder returns in a competitive collectibles market.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
